The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Many non-smokers are under the impression that lung cancer only affects people who smoke, and this belief makes them feel ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Edgardo S. Santos, MD, FACP, FASCO, emphasized the need to eliminate the stigma around smoking in lung cancer, highlighted the importance of early detection and discussed how advances in precision ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC ...